Business Context and Reporting Period
This Form 8-K Current Report was filed by Tempest Therapeutics, Inc. (TPST) on September 19, 2022. The report discloses changes in the Company's principal officers effective September 30, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of Pierre Lorenzo and the appointment of new officers:
- Resignation: Pierre Lorenzo resigned as Corporate Controller, Treasurer, Principal Accounting Officer, and Secretary. The resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointments:
- Justin Trojanowski was appointed Corporate Controller, Treasurer, and Principal Accounting Officer.
- Nicholas Maestas was appointed Secretary.
Management Commentary and Risks
Management confirmed that the transition of duties is planned and orderly. Justin Trojanowski brings prior experience from Nektar Therapeutics, Immune Design, and Ernst & Young. The filing states there are no arrangements or understandings regarding Mr. Trojanowski's selection that require disclosure, and no transactions involving him require disclosure under Item 404(a) of Regulation S-K. No specific risks or contingencies related to financial performance were disclosed in this document.
Investor Verification Checklist
- Verify the effective date of the officer transitions (September 30, 2022).
- Confirm the professional background of the new Corporate Controller, Justin Trojanowski, particularly his experience in the biopharmaceutical sector.
- Review subsequent filings for any impact on the Company's internal controls or financial reporting processes following the departure of the Principal Accounting Officer.